HUTCHMED Initiates Global Clinical Trial for Novel KRAS-EGFR-Antibody Conjugate Therapy in Solid Tumors

HUTCHMED (China) Limited has commenced the Phase Ia part of a global clinical trial for HMPL-A830, a first-in-class Antibody-Targeted Therapy Conjugate (ATTC), in patients with unresectable, advanced, or metastatic solid tumors. The therapy combines a potent KRAS small molecule inhibitor payload with an anti-EGFR antibody, aiming to deliver the inhibitor directly to EGFR-expressing tumors while simultaneously blocking EGFR and KRAS signaling to enhance efficacy and tolerability. The first patient received a dose in China on September 24, 2026.